Reduced muscle heath, physical inactivity, and more belly fat lowered sensitivity to insulin, a risk factor for diabetes, among adults…
Articles by Steve Bryson, PhD
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to PPL-001, Papillon Therapeutics‘ cell therapy for…
Widespread scar tissue in the lower left chamber of the heart — the left ventricle — correlated with genetic disease…
Larimar Therapeutics plans to launch a study by the end of the year that will test the pharmacological properties…
The U.S. Food and Drug Administration (FDA) has selected nomlabofusp, an investigational treatment for Friedreich’s ataxia (FA), to…
Researchers in a report described the first case of a Friedreich’s ataxia (FA) patient who developed photophobia, or an…
Voyager Therapeutics has selected a lead gene therapy candidate to advance into clinical trials with the aim of correcting…
Gene therapy safely reversed heart problems, lowered blood markers for heart muscle damage, and extended survival in a…
A deficiency in the frataxin protein, which is the underlying cause of Friedreich’s ataxia (FA), alters a process in…
Noninvasive diffusion MRI (dMRI) captured changes in the structure of the brain and brainstem of people with Friedreich’s ataxia…